Published in J Thyroid Res on June 14, 2011
Increasing incidence of thyroid cancer: controversies explored. Nat Rev Endocrinol (2013) 1.31
Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. J Clin Endocrinol Metab (2013) 0.90
Epigenetic modifications in human thyroid cancer. Biomed Rep (2014) 0.84
MTHFR C677T polymorphisms are associated with aberrant methylation of the IGF-2 gene in transitional cell carcinoma of the bladder. J Biomed Res (2012) 0.76
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
The epigenomics of cancer. Cell (2007) 30.91
The cancer genome. Nature (2009) 23.13
Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA (2006) 22.71
Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 18.36
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet (1998) 13.27
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (1998) 11.90
Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (1998) 10.89
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res (2003) 8.67
Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (1998) 7.81
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science (1999) 6.93
BRAF mutation in thyroid cancer. Endocr Relat Cancer (2005) 5.65
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab (2003) 4.93
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab (2005) 4.39
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol (1998) 2.64
DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet (2001) 2.50
High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res (2003) 2.49
RET/PTC rearrangement in thyroid tumors. Endocr Pathol (2002) 2.42
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Preferential response of cancer cells to zebularine. Cancer Cell (2004) 2.39
Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid (2010) 2.05
Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells. J Biol Chem (2006) 1.93
Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab (2003) 1.91
RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology (2006) 1.85
Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. Blood (2009) 1.69
Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res (2003) 1.65
Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery (1997) 1.43
Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res (1998) 1.39
Quantitative assessment of promoter methylation profiles in thyroid neoplasms. J Clin Endocrinol Metab (2005) 1.27
Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res (2010) 1.21
Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors: a marker of malignancy and a cause of gene silencing. Cancer Res (2003) 1.20
Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab (1999) 1.19
Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab (2005) 1.18
DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer (2002) 1.17
Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction. Methods (2002) 1.06
Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin Cancer Res (2004) 1.05
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab (2005) 1.04
Down-regulation and promoter methylation of tissue inhibitor of metalloproteinase 3 in choriocarcinoma. Gynecol Oncol (2004) 1.01
Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol (2005) 0.99
Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg (2010) 0.97
Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid (2010) 0.94
DAP-kinase--protector or enemy in apoptotic cell death. Int J Biochem Cell Biol (2005) 0.89
Expression of the apical iodide transporter in human thyroid tissues: a comparison study with other iodide transporters. J Clin Endocrinol Metab (2004) 0.88
Molecular pathology of parathyroid tumors. Trends Endocrinol Metab (2001) 0.81
DNA hypermethylation status of multiple genes in papillary thyroid carcinomas. Pathobiology (2007) 0.80
Prognosis and management of invasive well-differentiated thyroid cancer. Otolaryngol Clin North Am (2010) 0.76
K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science (2011) 5.40
Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet (2013) 2.09
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer (2002) 1.51
Stump appendicitis: a surgeon's dilemma. JSLS (2011) 1.32
Comprehensive re-sequencing of adrenal aldosterone producing lesions reveal three somatic mutations near the KCNJ5 potassium channel selectivity filter. PLoS One (2012) 1.30
Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J Clin Endocrinol Metab (2012) 1.26
Spontaneous adrenal hemorrhage with associated masses: etiology and management in 6 cases and a review of 133 reported cases. World J Surg (2012) 1.26
25-hydroxyvitamin D(3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab (2002) 1.24
Familial parathyroid tumors: diagnosis and management. World J Surg (2009) 1.05
Adrenocortical Carcinoma: Current Therapeutic State-of-the-Art. J Oncol (2012) 1.05
Parathyroid four-dimensional computed tomography: evaluation of radiation dose exposure during preoperative localization of parathyroid tumors in primary hyperparathyroidism. World J Surg (2012) 1.03
4D parathyroid CT as the initial localization study for patients with de novo primary hyperparathyroidism. Ann Surg Oncol (2010) 1.00
Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. J Clin Endocrinol Metab (2014) 0.94
The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer (2014) 0.94
The risk of second cancers after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid (2013) 0.93
BRAFV600E mutation in papillary thyroid microcarcinoma: a genotype-phenotype correlation. Mod Pathol (2012) 0.93
Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer (2012) 0.93
Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Curr Opin Oncol (2009) 0.92
Frequent germ-line mutations of the MEN1, CASR, and HRPT2/CDC73 genes in young patients with clinically non-familial primary hyperparathyroidism. Horm Cancer (2012) 0.91
Involvement of the MEN1 gene locus in familial isolated hyperparathyroidism. Eur J Endocrinol (2002) 0.91
The DNA methylome of benign and malignant parathyroid tumors. Genes Chromosomes Cancer (2011) 0.90
Insular variant of poorly differentiated thyroid carcinoma. Endocr Pract (2011) 0.89
Trans-oral Vestibular Endocrine Surgery: A New Technique in the United States. Ann Surg (2016) 0.88
Reflex BRAF testing in thyroid fine-needle aspiration biopsy with equivocal and positive interpretation: a prospective study. Thyroid (2011) 0.87
Loss of heterozygosity on the short arm of chromosome 1 in pheochromocytoma and abdominal paraganglioma. World J Surg (2002) 0.87
The tumor suppressor gene RIZ in cancer gene therapy (review). Oncol Rep (2001) 0.87
Defining surgical therapy for pseudomembranous colitis with toxic megacolon. J Clin Gastroenterol (2008) 0.86
Vanishing thyroid tumors: a diagnostic dilemma after ultrasonography-guided fine-needle aspiration. Thyroid (2012) 0.86
Clinical and histopathological characteristics of hyperparathyroidism-induced hypercalcemic crisis. World J Surg (2011) 0.85
Minimally invasive parathyroidectomy. Int J Endocrinol (2011) 0.85
Follicular variant of papillary thyroid carcinoma: accuracy of FNA diagnosis and implications for patient management. Endocr Pathol (2014) 0.85
Evidence of a stabilizing mutation of β-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas. Endocrine (2012) 0.83
Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology (2012) 0.83
Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal paragangliomas. Int J Oncol (2005) 0.83
Allelic loss in clinically and screening-detected primary hyperparathyroidism. Clin Endocrinol (Oxf) (2002) 0.82
Risk stratification in follicular neoplasm: a cytological assessment using the modified Bethesda classification. Cancer Cytopathol (2014) 0.81
Expression and somatic mutations of SDHAF2 (SDH5), a novel endocrine tumor suppressor gene in parathyroid tumors of primary hyperparathyroidism. Endocrine (2010) 0.79
Surgical approach and outcomes in patients with lithium-associated hyperparathyroidism. Ann Surg Oncol (2012) 0.78
In situ RNA-RNA hybridisation of phospholipase C beta 3 shows lack of expression in neuroendocrine tumours. Anticancer Res (2003) 0.78
Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma. Mol Cancer (2013) 0.78
Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma. Surgery (2013) 0.77
Multiple endocrine neoplasia type 1 polymorphism D418D is associated with sporadic primary hyperparathyroidism. Surgery (2002) 0.77
Loss of heterozygosity in parathyroid glands of familial hypercalcemia with hypercalciuria and point mutation in calcium receptor. J Clin Endocrinol Metab (2002) 0.76
Sorting through the evidence of adult pneumatosis intestinalis as a harbinger for disaster vs benign disease. Arch Surg (2011) 0.75
Parathyroidectomy in familial hypercalcemia with clinical characteristics of primary hyperparathyroidism and familial hypocalciuric hypercalcemia. Surgery (2002) 0.75
Advances in understanding the molecular underpinnings of adrenocortical tumors. Curr Opin Oncol (2017) 0.75
Pancreaticoduodenectomy Can Be Performed Safely with Rare Employment of Surgical Drains. Am Surg (2017) 0.75
Considering Postoperative Functional Hypoaldosteronism after Unilateral Adrenalectomy. Am Surg (2017) 0.75
Laryngeal physiology and voice acoustics are maintained after minimally invasive parathyroidectomy. Ann Surg (2013) 0.75
Multinodular goiter and primary hyperparathyroidism: a circuitous route to diagnosing metastatic uveal melanoma. Endocr Pathol (2008) 0.75